A composition for reducing microbial activity in an environment susceptible to microbial activity, comprising: metallic nanoparticles; and an oxygenation agent.

A composition for reducing microbial activity in an environment susceptible to microbial activity, comprising: metallic nanoparticles; and an oxygenation agent.

The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a proton (H.sup.+) in water and a compound that generates a hypochlorite anion (OCl.sup.−) in water to thereby produce air-free hypochlorous acid.

The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a proton (H.sup.+) in water and a compound that generates a hypochlorite anion (OCl.sup.−) in water to thereby produce air-free hypochlorous acid.

A pharmaceutical composition that is orally applied and that counteracts reproduction and the spread of influenza viruses, in particular influenza viruses of the so-called covid species and their mutations, comprises a pharmaceutically acceptable carrier and at least a first virucidal component designed to unfold antiviral activity when activated, which first virucidal component is sodium chlorite that is dissolved in saliva when the pharmaceutical composition has been applied to a person.

A pharmaceutical composition that is orally applied and that counteracts reproduction and the spread of influenza viruses, in particular influenza viruses of the so-called covid species and their mutations, comprises a pharmaceutically acceptable carrier and at least a first virucidal component designed to unfold antiviral activity when activated, which first virucidal component is sodium chlorite that is dissolved in saliva when the pharmaceutical composition has been applied to a person.

Systems and methods for treating drug resistant pneumonia and tuberculosis using hypochlorous acid (HOCl) are disclosed. Embodiments of the present disclosure relate to nebulizing HOCl as a method of treating drug resistant bacteria, in particular, bacterial pneumonia pathogens (i.e., Streptococcus pneumoniae) and Mycobacterium tuberculosis bacteria. The nebulized HOCl solution may be approximately 180 parts per million (PPM) of the aqueous solution and have a pH of less than 6.

Systems and methods for treating drug resistant pneumonia and tuberculosis using hypochlorous acid (HOCl) are disclosed. Embodiments of the present disclosure relate to nebulizing HOCl as a method of treating drug resistant bacteria, in particular, bacterial pneumonia pathogens (i.e., Streptococcus pneumoniae) and Mycobacterium tuberculosis bacteria. The nebulized HOCl solution may be approximately 180 parts per million (PPM) of the aqueous solution and have a pH of less than 6.

Bacterial infections in dairy cattle are treated by applying a solution of acidified sodium chlorite/chlorine dioxide to the hooves of the animals. Preferably, the solution is applied to the hooves by placing the solution in a foot bath and guiding the animals through the foot bath.

Bacterial infections in dairy cattle are treated by applying a solution of acidified sodium chlorite/chlorine dioxide to the hooves of the animals. Preferably, the solution is applied to the hooves by placing the solution in a foot bath and guiding the animals through the foot bath.